RNA Editing
Experimental RNAi
CRISPR/Cas9 Genome Editing
CRISPR
RNA Interference
CRISPR and crRNAs
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Dec 28, 2025

A Nonsequencing Approach for the Rapid Detection of RNA Editing
Published on: April 21, 2022
1Laboratorio de Investigación en Genómica, Genética y Bioinformática, Torre de Hemato-Oncología, 4to Piso, Sección 2, Hospital Infantil de México, Federico Gómez, Mexico City 06720, Mexico.
This article reviews four new technologies that use the body's own enzymes to fix genetic errors in RNA. By guiding these natural tools to specific locations, scientists can correct disease-causing mutations without changing the underlying DNA. These methods offer a promising, precise way to treat genetic conditions while avoiding permanent genomic alterations.
Area of Science:
Background:
No prior work had fully synthesized the rapid evolution of programmable RNA-editing platforms. That uncertainty drove the need to evaluate how natural enzymes are harnessed for therapeutic precision. Prior research has shown that adenosine-to-inosine conversion represents a common post-transcriptional modification. Scientists have long sought ways to direct these changes toward specific genetic targets. This gap motivated the development of systems that recruit endogenous enzymes to precise locations. Current literature highlights several distinct platforms designed for this exact purpose. These tools utilize guide molecules to direct enzymatic activity toward chosen transcripts. Such advancements represent a shift in how researchers approach the correction of point mutations.
Purpose Of The Study:
The aim of this review is to analyze the current status and rapid progress of novel ADAR-mediated RNA-editing systems. The author seeks to highlight the unique qualities of each recently engineered platform. This work addresses the need for a comprehensive overview of how these tools function in mammalian cells. The study explores how these strategies recruit human enzymes to endogenous transcripts. The author intends to clarify the potential of these systems for understanding gene expression regulation. This research also examines the capacity of these tools to correct clinically relevant mutations. The study provides a critical look at the challenges that must be addressed for future therapeutic use. The author aims to provide a clear perspective on the future of programmable RNA modification.
Main Methods:
The review approach involves a systematic analysis of four recently developed molecular platforms. The author evaluates the structural design and functional capabilities of each system. This examination focuses on how these tools recruit endogenous enzymes to specific target sequences. The analysis synthesizes data from studies conducted in various mammalian cell models. The author compares the programmability and efficiency of these distinct RNA-targeting strategies. This assessment highlights the mechanisms used to achieve precise base conversions. The review also considers the potential for correcting disease-associated mutations within full-length transcripts. Finally, the author discusses the current limitations regarding delivery and off-target activity.
Main Results:
Key findings from the literature indicate that these four platforms achieve precise base conversions in mammalian cells. The systems demonstrate high levels of programmability for targeting specific RNA transcripts. Research shows that these tools effectively recruit endogenous enzymes to perform adenosine-to-inosine modifications. The literature confirms that these methods allow for the correction of point mutations without modifying the host genome. Studies highlight that these platforms are capable of editing full-length transcripts with significant efficiency. The findings suggest that these tools provide a versatile alternative for in vivo research applications. The literature notes that while these systems are promising, off-target edits remain a challenge for current designs. The author reports that these strategies represent a major advancement in the field of RNA-based therapeutics.
Conclusions:
The authors propose that these platforms offer a versatile toolkit for precise genetic correction. They suggest that these systems effectively bypass the risks associated with permanent genomic alterations. The researchers note that the ability to target full-length transcripts remains a significant advantage for clinical utility. They highlight that overcoming off-target effects is necessary for future therapeutic implementation. The authors argue that these tools provide a straightforward method for studying gene regulation. They emphasize that delivery challenges must be resolved to enable widespread in vivo application. The researchers conclude that these systems represent a major step toward programmable molecular medicine. They maintain that continued refinement will likely improve the specificity of these editing strategies.
The researchers propose that these platforms function by recruiting endogenous adenosine deaminase acting on RNA enzymes to specific transcripts. This mechanism allows for precise base conversion without altering the underlying genomic sequence, distinguishing it from traditional gene-editing approaches that modify DNA directly.
The authors characterize four distinct platforms: CIRTS, RESCUE, RESTORE, and LEAPER. Each system utilizes unique guide architectures to direct enzymatic activity, providing researchers with diverse options for targeting specific sequences within mammalian cells.
The authors state that these systems are necessary for addressing disease-causing point mutations without permanent genomic changes. By targeting RNA rather than DNA, these tools avoid the risks of unintended, irreversible alterations to the host genome.
These platforms utilize guide molecules to recruit endogenous enzymes. This approach allows for the programmable modification of transcripts, offering a flexible alternative to methods that require the expression of exogenous, potentially immunogenic proteins.
The researchers measure success through the efficiency and specificity of base conversions. They emphasize that minimizing off-target edits is a key metric for evaluating the clinical potential of these tools compared to earlier, less precise methods.
The authors propose that these systems could eventually serve as therapeutic tools for treating genetic disorders. They suggest that once delivery and off-target challenges are resolved, these platforms may provide a viable path for correcting mutations in a clinical setting.